Search

for
Search:

GlossaryGefitinib (ZD1839)

inhibits EGFR to treat certain non-small cell lung cancers

Gefitinib, also known as Iressa, is a medication used to treat certain types of non-small cell lung cancer. It works by inhibiting the epidermal growth factor receptor (EGFR), which is involved in the growth and spread of cancer cells. By blocking this receptor, gefitinib can help slow down or stop the progression of the cancer.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 26 results

research Follicular and Epidermal Alterations in Patients Treated with ZD1839 (Iressa), an Inhibitor of the Epidermal Growth Factor Receptor

169 citations, September 2002 in “British journal of dermatology/British journal of dermatology, Supplement”

ZD1839 (Iressa) causes skin and hair side effects, treatable with tretinoin cream and minocycline.

research Acneiform Eruptions Caused by an Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor ZD1839

1 citations, March 2004 in “Journal of the American Academy of Dermatology”

ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.

research Cutaneous Adverse Effects of Targeted Therapies

192 citations, January 2015 in “Journal of the American Academy of Dermatology”

Targeted cancer therapies often cause serious skin problems that need careful management.

research Classification and Management of Skin, Hair, Nail, and Mucosal Side Effects of Epidermal Growth Factor Receptor Inhibitors

138 citations, February 2007 in “European journal of cancer”

EGFR inhibitors often cause skin problems and other side effects, but these are usually reversible and can be managed to keep patients comfortable.

research Trichomegaly of the Eyelashes Following Treatment with Cetuximab

78 citations, June 2005 in “Annals of oncology”

Cetuximab can cause excessive eyelash growth.

View more "zd1839" in research →

Community Join

0 / 0 results

— no results